Cefaly is a clinically validated migraine treatment device that uses neuromodulation to provide drug-free relief for acute attacks and prevention. It is designed for home use and FDA-cleared as a wearable neurological device to reduce migraine pain and attacks, targeting nerve pathways involved in migraine. The company operates primarily in the United States with a presence in Europe and other regions, and it offers patient support, clinical studies, and a connected CeCe app for migraine management.
No recent news for this company.
No recent deals for this company.